We came across a bullish\u00a0thesis on\u00a0Intellia Therapeutics, Inc.\u00a0on\u00a0Danny\u2019s Substack\u00a0by\u00a0Danny Green. In this article,\u00a0we will summarize the\u00a0bulls\u2019\u00a0thesis on\u00a0NTLA.\u00a0Intellia Therapeutics, Inc.’s\u00a0share was trading at $12.48\u00a0as of\u00a0February 18th.<\/p>\n Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments.\u00a0NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its pioneering work in in-vivo CRISPR gene editing. The company is among the first to demonstrate systemic CRISPR efficacy in humans, targeting diseases like ATTR amyloidosis and hereditary angioedema, with one-time treatments that could replace chronic therapies.<\/p>\n If successful, this positions Intellia at the forefront of a new drug category\u2014genomic surgery\u2014validated by partnerships with major pharma players such as Regeneron, Novartis, and Vertex. While regulatory standards are still evolving and long-term safety remains unproven, the platform\u2019s potential for expansion across multiple monogenic diseases offers enormous optionality.<\/p>\n Intellia\u2019s market opportunity is significant, with ATTR and HAE representing multi-billion-dollar markets and pricing for one-time therapies expected between $500,000 and $2 million per patient. Gross margins for such therapies could exceed 80%, and the platform could eventually extend into oncology and CNS disorders.<\/p>\n The company has a strong balance sheet, typically maintaining over $700 million in cash, supported by partner funding, and a low-debt structure, providing a runway of 2\u20133 years without additional financing. Institutional backing is robust, with major biotech funds and Regeneron holding significant stakes, although volatility in risk-off markets could pressure the stock.<\/p>\n The path to value creation is clear, with upcoming catalysts including Phase 2\/3 data for NTLA-2001 (ATTR), Phase 2 data for NTLA-2002 (HAE), FDA regulatory feedback, and potential commercial filings. While clinical setbacks, long-term safety issues, or competitive advances could severely impact the stock, the bull case is compelling: multiple approved drugs could validate the platform and drive a $20\u201330 billion market capitalization. Intellia offers a high-risk, high-reward proposition for investors willing to back a true biotech innovator poised to redefine treatment paradigms.<\/p>\n Previously, we covered a\u00a0bullish thesis<\/b>\u00a0on CRISPR Therapeutics AG (CRSP) by MADD-Scientis\u00a0in March 2025, which highlighted\u00a0Casgevy\u2019s\u00a0commercial potential, early patient uptake, outcomes-based reimbursement, and a strong pipeline including in vivo liver editing. CRSP\u2019s stock price has appreciated by approximately 30.63% since our coverage.<\/strong> Danny Green shares a similar view but emphasizes Intellia Therapeutics, Inc.\u2019s (NTLA) in-vivo CRISPR work and optionality across monogenic diseases.<\/p>\n<\/p><\/div>\n<\/div>\n<\/div>